1. Brazil Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biomm SA

Biomm SA

5.90
BRL
-0.06
(-1.01%)
0.18EPS
28.05P/E
866.28MMarket Cap
Biomm SA
B3:BIOM3
(B3)

Recent

price

5.90

P/E

ratio

28.05

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
BRL
0.05
- -
- -
- -
- -
- -
- -
- -
0.03
0.17
0.9
1.49
1.39
1.38
1.14
2.08
2.86
Revenue per Share
-0.23
-0.26
-0.73
-0.5
-0.37
0.24
-1.34
-1.07
-0.94
-1.08
-1.09
-1.11
-1.22
-0.94
-0.61
-0.05
0.23
Basic EPS, GAAP
-0.28
-0.15
-0.42
-2.12
-1.17
-1.4
-2.97
-1.69
-1.04
-1.66
-1.53
-1.41
-0.91
-0.94
-0.89
-1.03
-0.75
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.22
-0.48
-1.21
3.27
3.12
3.35
1.92
1.52
2.07
2.37
2.65
1.54
1.84
1.3
2.01
2.29
2.38
Book Value per Share
-0.37
-0.49
-1.22
2.75
2.33
2.53
1.06
0.76
1.48
1.39
1.84
0.77
1.28
0.85
1.66
1.83
1.89
Tangible Book Value per Share
18
18
19
20
34
34
34
36
45
52
65
72
76
86
126
129
134
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
- -
- -
2
9
59
107
105
118
143
269
384
Sales/Revenue/Turnover
-483.69
- -
- -
- -
- -
- -
- -
-34,389.32
-2,341.89
-588.22
-94.49
-61.3
-82.17
-61.04
-56.53
-1.78
10.61
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
2
5
10
12
12
11
12
9
11
Depreciation Expense
-4
-5
-14
-10
-13
8
-46
-38
-43
-56
-71
-80
-93
-81
-77
-7
30
Net Income, GAAP
- -
- -
- -
- -
- -
46.98
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.38
Effective Tax Rate (%)
-487.23
- -
- -
- -
- -
- -
- -
-37,017.48
-2,717.88
-624.02
-120.62
-74.95
-88.19
-68.65
-54.05
-2.48
7.89
Profit Margin (%)
-2
-5
-15
85
104
117
32
21
69
87
135
63
91
44
153
155
130
Working Capital
- -
11
12
15
62
82
113
135
131
143
145
134
121
106
77
51
35
LT Debt
-4
-9
-22
109
107
115
66
59
106
154
191
112
159
123
263
314
325
Total Equity
- -
- -
- -
- -
- -
4.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
6.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.88
Return on Capital (%)
- -
- -
- -
- -
-11.77
7.45
-50.38
-60.89
-51.47
-42.99
-41.02
-52.97
-68.39
-57.54
-40.05
-2.32
10.77
Return on Common Equity (%)

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46
54
73
LT Borrowings
51
50
35
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
137
137
137
Market Capitalization
988
1,040
866

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
281
322
367
Cash, Cash Equivalents & STI
43
31
10
Accounts Receivable, Net
109
81
66
Inventories
97
183
253
Total Current Liabilities
126
182
237
Payables & Accruals
- -
- -
- -
ST Debt
46
54
73
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.68%
22.24%
19.3%
Free Cash Flow
19.09%
8.89%
19.22%
Net Income, GAAP
-67.73%
-15.95%
-91.34%
Sales/Revenue/Turnover
- -
40.51%
88.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39
32
32
40
143
2025
40
27
36
167
269
2026
92
89
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.14
-0.12
-0.2
-0.61
2025
-0.1
-0.11
-0.08
0.21
-0.05
2026
0.07
0.01
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biomm S.A. (BIOM3.SA) is a biotechnology company focused on the development, manufacturing, and commercialization of high-value biological products, including biosimilars, biopharmaceuticals, and innovative therapies for chronic diseases. The company offers a portfolio of products such as recombinant human insulin and its analogs (e.g., glargine), monoclonal antibodies for oncology and autoimmune conditions, erythropoietins, and other complex biologics; it also provides contract development and manufacturing organization (CDMO) services for third-party biopharmaceutical production. Biomm operates primarily in Brazil with expanding presence in Latin America and select international markets, targeting public health systems, private healthcare providers, and global pharmaceutical partners; headquartered in Nova Lima, Minas Gerais, Brazil, the company was founded in 2012. In recent developments, Biomm completed a significant capital increase through a public offering in 2024, bolstering its expansion plans, and announced a strategic partnership with a leading global biotech firm for technology transfer in advanced gene therapies in early 2025. The company launched its first domestically produced biosimilar insulin glargine in Brazil in late 2024, marking a milestone in reducing import dependency for diabetes treatments, and acquired a complementary CDMO facility to enhance production capacity for monoclonal antibodies. These initiatives reflect Biomm's shift toward greater self-sufficiency in complex biologics manufacturing and entry into emerging segments like cell and gene therapies.